Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in ...

Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor ...

AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy ...

Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 ...

Noon - 12:30 p.m. Wave 1 check-in UCC Atrium 12:30 - 2:30 p.m. Wave 1 poster presentations UCC Atrium and 2nd Floor ... For both options, students must first submit an abstract for approval by their ...

The ICAR-Central Marine Fisheries Research Institute (CMFRI) will host the fourth International Symposium on Marine ...

Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - ...

Q1 2025 Earnings Call Transcript May 12, 2025 Xenon Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.83, ...

Key data being presented at EHA 2025 include: The accepted abstracts listed below are now available online at the EHA conference website. Copies of the oral and poster presentations will be made ...